Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Moleculin Biotech, Inc. (MBRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/25/2022 |
8-K
| Quarterly results|
Docs:
|
"-- Financial Tables Follow-- Moleculin Biotech, Inc. Unaudited Condensed Consolidated Balance Sheets Current assets: Cash and cash equivalents $ 70,903 $ 15,173 Prepaid expenses and other current assets 1,594 2,025 Total current assets 72,497 17,198 Furniture and equipment, net 338 483 Intangible assets 11,148 11,148 Operating lease right-of-use asset 107 202 Total assets $ 84,090 $ 29,031 Current liabilities: Accounts payable and accrued expenses and other current liabilities $ 3,622 $ 2,920 Total current liabilities 3,622 2,920 Operating lease liability - long-term, net of current portion 63 159 Warrant liability - long term 1,412 8,192 Total liabilities 5,097 11,271 Total stockholders' equity 78,993 17,760 Total liabilities and stockholders' equity $ 84,090 $ 29,031 Unaudited Condensed ..." |
|
| 11/12/2021 |
8-K
| Quarterly results|
Docs:
|
"-- Financial Tables Follow-- Moleculin Biotech, Inc. Unaudited Condensed Consolidated Balance Sheets Current assets: Cash and cash equivalents $ 75,178 $ 15,173 Prepaid expenses and other current assets 1,892 2,025 Total current assets 77,070 17,198 Furniture and equipment, net 353 483 Intangible assets 11,148 11,148 Operating lease right-of-use asset 131 202 Total assets $ 88,702 $ 29,031 Current liabilities: Accounts payable and accrued expenses and other current liabilities $ 3,656 $ 2,920 Total current liabilities 3,656 2,920 Operating lease liability - long-term, net of current portion 75 159 Warrant liability - long term 3,712 8,192 Total liabilities 7,443 11,271 Total stockholders' equity 81,259 17,760 Total liabilities and stockholders' equity $ 88,702 $ 29,031 Unaudited Condensed ..." |
|
| 08/12/2021 |
8-K
| Quarterly results|
Docs:
|
"-- Financial Tables Follow-- Moleculin Biotech, Inc. Unaudited Condensed Consolidated Balance Sheets Current assets: Cash and cash equivalents $ 79,506 $ 15,173 Prepaid expenses and other current assets 2,330 2,025 Total current assets 81,836 17,198 Furniture and equipment, net 395 483 Intangible assets 11,148 11,148 Operating lease right-of-use asset 155 202 Total assets $ 93,534 $ 29,031 Current liabilities: Accounts payable and accrued expenses and other current liabilities $ 3,350 $ 2,920 Total current liabilities 3,350 2,920 Operating lease liability - long-term, net of current portion 94 159 Warrant liability - long term 5,390 8,192 Total liabilities 8,834 11,271 Total stockholders' equity 84,700 17,760 Total liabilities and stockholders' equity $ 93,534 $ 29,031 Unaudited Condensed ..." |
|
| 05/12/2021 |
8-K
| Quarterly results |
| 03/24/2021 |
8-K
| Quarterly results |
| 11/13/2020 |
8-K
| Quarterly results|
Docs:
|
"Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020 HOUSTON, November 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., , a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended September 30, 2020 and provided a business update. Management Discussion "We are extremely encouraged by the progress we made in the third quarter. Despite the sustained headwinds from the COVID-19 pandemic, we were able to drive the development of Annamycin both in our AML and lung indications, further progress our clinical trials for WP1066, expand and accelerate our infectious disease platform, and bolster our experienced leadership team,” com..." |
|
| 08/12/2020 |
8-K
| Quarterly results |
| 03/19/2020 |
8-K
| Quarterly results|
Docs:
|
"Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2019 HOUSTON, March 19, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., , a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced its financial results for the year ended December 31, 2019 and provided a business update. Management Discussion Walter Klemp, Chairman and CEO of Moleculin, stated, "2019 marked a pivotal year for Moleculin, as we achieved several key milestones in our three core technologies and six oncology drug candidates, strengthened our financial position, and bolstered our leadership team. Notably, we are extremely excited by the progress we made advancing our lead candidate, Annamycin, a ‘next generation anthracycli..." |
|
| 11/12/2019 |
8-K
| Quarterly results |
| 08/16/2019 |
8-K
| Quarterly results |
| 05/14/2019 |
8-K
| Quarterly results |
| 02/21/2019 |
8-K
| Quarterly results |
| 11/13/2018 |
8-K
| Quarterly results |
| 08/13/2018 |
8-K
| Quarterly results |
| 03/28/2018 |
8-K
| Quarterly results |
| 11/14/2017 |
8-K
| Quarterly results |
| 08/14/2017 |
8-K
| Quarterly results|
Docs:
|
"Moleculin Biotech, Inc. Balance Sheets Assets Current assets: Cash and cash equivalents $ 9,272 $ 5,007 Prepaid expenses 809 215 Total current assets 10,081 5,222 Furniture and equipment, net of accumulated depreciation of $14 and $6, respectively 20 23 Intangible assets 11,148 11,148 Total assets $ 21,249 $ 16,393 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable and accrued expenses $ 645 $ 1,069 Convertible notes payable — 276 Warranty liability – current portion 1,185 — Total current liabilities 1,830 1,345 Warrant liability — — Long-term deferred compensation – related party 150 88 Total liabilities 1,980 1,433 Commitments and contingencies Stockholders’ equity Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding — —..." |
|
| 05/16/2017 |
8-K
| Form 8-K - Current report |
| 04/03/2017 |
8-K
| Quarterly results|
Docs:
|
"Moleculin Biotech, Inc. Balance Sheets December 31, 2016 December 31, 2015 Assets Current Assets: Cash and cash equivalents $ 5,007,216 $ 28,091 Prepaid expenses 215,052 – Total current assets 5,222,268 28,091 Long-Term Assets: Furniture and equipment, net of accumulated depreciation of $6,162 and $0, respectively 23,128 – Intangible assets 11,147,540 – Total Assets $ 16,392,936 $ 28,091 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable and accrued expenses $ 1,048,655 $ 322,790 Convertible notes payable 296,412 450,000 Total current liabilities 1,345,067 772,790 Long-term deferred compensation – related party 87,500 – Total Liabilities 1,432,567 772,790 Commitments and contingencies Stockholders' Equity: Preferred stock, $0.001 par value; 5,000,000 authorized, no ..." |
|
| 11/21/2016 |
8-K
| Form 8-K - Current report |
| 08/18/2016 |
8-K
| Quarterly results|
Docs:
|
"Statement of Operations For the Three Months Ended June 30, 2016 For the Six Months Ended June 30, 2016 Revenue $ – $ – Operating expenses: Research and development 361,728 376,728 General and administrative 618,001 923,572 Depreciation 652 652 Total operating expenses 980,381 1,300,952 Loss from operations Other expense: Interest expense Net loss $ $ Net loss per common share - basic and diluted $ $ Weighted average common shares outstanding - basic and diluted 8,875,173 7,796,782 Moleculin Biotech, Inc. Statements of Cash Flows" |
|
| 06/17/2016 |
8-K
| Quarterly results |
|
|